Contact:
4008465777
-
About Us
News & Events
-
04-24
Tonghua Dongbao's Entire Insulin Lineup Secures Category A in the VBP Program, With Two Types Categorized as A1
On April 23, 2024, China's Joint Procurement Office (JPO) announced the preliminarily selected bids from a continued round of the national volume-based procurement (VBP) program for insulin. This ...
-
03-29
Tonghua Dongbao releases 2023 sustainability report
On March 28, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2023 sustainability report. The report disclosed ...
-
03-29
Tonghua Dongbao achieves record product sales in 2023, driving performance growth
Performance summaryIn 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") reported:RMB 3.075 billion in revenue, an incre...
-
02-22
Tonghua Dongbao: First Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) meets primary endpoint in phase I clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase I pivotal ...
-
02-07
Tonghua Dongbao announces NMPA acceptance of clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) intended for weight loss indications
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
-
01-17
Tonghua Dongbao: novel URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint in phase IIa clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a multicenter, ran...